Nanotechnology and Nanocarrier-Based Drug Delivery as the Potential Therapeutic Strategy for Glioblastoma Multiforme: An Update

Hsu, Jen‐Fu; Chu, Shih-Ming; Liao, Chen-Chu; Wang, Chao-Jan; Wang, Yishan; Lai, Ming-Wei; Wang, Hsiao-Chin; Huang, Hsuan-Rong; Tsai, Ming-Horng

doi:10.3390/cancers13020195

Cited by 81 publications

(57 citation statements)

References 165 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This liposome suspension presented long-term stability with a homogeneous size (PDI < 0.2) around 100 nm. Consequently, they present key characteristics of nanocarriers used to target GBM ( Figure 6 a,b) [ 49 , 50 ]. Indeed, drug delivery devices should present a size <150 nm to enter and exit fenestrated capillaries in the tumor microenvironment and reach the carcinogenic cells [ 51 ].…”

Section: Discussionmentioning

confidence: 99%

A New Chalcone Derivative with Promising Antiproliferative and Anti-Invasion Activities in Glioblastoma Cells

et al. 2021

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most common and most deadly primary malignant brain tumor. Current therapies are not effective, the average survival of GBM patients after diagnosis being limited to few months. Therefore, the discovery of new treatments for this highly aggressive brain cancer is urgently needed. Chalcones are synthetic and naturally occurring compounds that have been widely investigated as anticancer agents. In this work, three chalcone derivatives were tested regarding their inhibitory activity and selectivity towards GBM cell lines (human and mouse) and a non-cancerous mouse brain cell line. The chalcone 1 showed the most potent and selective cytotoxic effects in the GBM cell lines, being further investigated regarding its ability to reduce critical hallmark features of GBM and to induce apoptosis and cell cycle arrest. This derivative showed to successfully reduce the invasion and proliferation capacity of tumor cells, both key targets for cancer treatment. Moreover, to overcome potential systemic side effects and its poor water solubility, this compound was encapsulated into liposomes. Therapeutic concentrations were incorporated retaining the potent in vitro growth inhibitory effect of the selected compound. In conclusion, our results demonstrated that this new formulation can be a promising starting point for the discovery of new and more effective drug treatments for GBM.

show abstract

Section: Discussionmentioning

confidence: 99%

A New Chalcone Derivative with Promising Antiproliferative and Anti-Invasion Activities in Glioblastoma Cells

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Here, we review the nano-carrier systems which we believe are most suitable for clinical translation: liposomes and polymeric micelles, exosomes, and some biomimetic systems. Other nanomedicine formulations for BBB drug delivery, including metal particles and silica are reviewed elsewhere [ 41 ]. A selection of key studies are highlighted in Table 1 .…”

Section: Nanomedicinesmentioning

confidence: 99%

“…Other inorganic nanoparticles such as silica, gold, iron-based IONPs and carbon-based nanoparticles for BBB theranostics are recently reviewed elsewhere [ 41 , 89 ].…”

Section: Inorganic Nanoparticlesmentioning

confidence: 99%

Emerging Nano-Carrier Strategies for Brain Tumor Drug Delivery and Considerations for Clinical Translation

2021

View full text Add to dashboard Cite

Treatment of brain tumors is challenging since the blood–brain tumor barrier prevents chemotherapy drugs from reaching the tumor site in sufficient concentrations. Nanomedicines have great potential for therapy of brain disorders but are still uncommon in clinical use despite decades of research and development. Here, we provide an update on nano-carrier strategies for improving brain drug delivery for treatment of brain tumors, focusing on liposomes, extracellular vesicles and biomimetic strategies as the most clinically feasible strategies. Finally, we describe the obstacles in translation of these technologies including pre-clinical models, analytical methods and regulatory issues.

show abstract

“…The last few decades have seen considerable progress in nanotechnology, offering a multitude of opportunities and possibilities to overcome these shortcomings. Apart from improving the bioavailability, the drug efficacy was largely improved by the controlled drug release of these nanocarriers [298]. Several stimuli such as temperature [299], pH [300] and redox sensitivity [301] were shown to trigger and enhance the release of the drug cargo in selected locations.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Do Lipid-based Nanoparticles Hold Promise for Advancing the Clinical Translation of Anticancer Alkaloids?

Loh

Tan

Lee

et al. 2021

Cancers

View full text Add to dashboard Cite

Since the commercialization of morphine in 1826, numerous alkaloids have been isolated and exploited effectively for the betterment of mankind, including cancer treatment. However, the commercialization of alkaloids as anticancer agents has generally been limited by serious side effects due to their lack of specificity to cancer cells, indiscriminate tissue distribution and toxic formulation excipients. Lipid-based nanoparticles represent the most effective drug delivery system concerning clinical translation owing to their unique, appealing characteristics for drug delivery. To the extent of our knowledge, this is the first review to compile in vitro and in vivo evidence of encapsulating anticancer alkaloids in lipid-based nanoparticles. Alkaloids encapsulated in lipid-based nanoparticles have generally displayed enhanced in vitro cytotoxicity and an improved in vivo efficacy and toxicity profile than free alkaloids in various cancers. Encapsulated alkaloids also demonstrated the ability to overcome multidrug resistance in vitro and in vivo. These findings support the broad application of lipid-based nanoparticles to encapsulate anticancer alkaloids and facilitate their clinical translation. The review then discusses several limitations of the studies analyzed, particularly the discrepancies in reporting the pharmacokinetics, biodistribution and toxicity data. Finally, we conclude with examples of clinically successful encapsulated alkaloids that have received regulatory approval and are undergoing clinical evaluation.

show abstract

Nanotechnology and Nanocarrier-Based Drug Delivery as the Potential Therapeutic Strategy for Glioblastoma Multiforme: An Update

Cited by 81 publications

References 165 publications

A New Chalcone Derivative with Promising Antiproliferative and Anti-Invasion Activities in Glioblastoma Cells

A New Chalcone Derivative with Promising Antiproliferative and Anti-Invasion Activities in Glioblastoma Cells

Emerging Nano-Carrier Strategies for Brain Tumor Drug Delivery and Considerations for Clinical Translation

Do Lipid-based Nanoparticles Hold Promise for Advancing the Clinical Translation of Anticancer Alkaloids?

Contact Info

Product

Resources

About